REFERENCES
1. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020;382:545-53.
2. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011;118:3273-9.
3. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
4. “CAR-NK”|Recruiting, Active, not recruiting Studies|Cancer. Available from: https://classic.clinicaltrials.gov/ct2/results?term=%22CAR-NK%22&cond=Cancer&Search=Apply&recrs=a&recrs=d&age_v=&gndr=&type=&rslt= [Last accessed on 4 Dec 2023].
5. Djaoud Z, Parham P. HLAs, TCRs, and KIRs, a triumvirate of human cell-mediated immunity. Annu Rev Biochem 2020;89:717-39.
6. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000;61:65-73.
7. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
8. Felices M, Miller JS. Targeting KIR blockade in multiple myeloma: trouble in checkpoint paradise? Clin Cancer Res 2016;22:5161-3.
9. Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood 2023;141:856-68.
10. Search Results|Beta ClinicalTrials.gov. Available from: https://clinicaltrials.gov/search?intr=lirilumab&aggFilters=status:act%20rec%20not [Last accessed on 4 Dec 2023].
11. Li Y, Basar R, Wang G, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med 2022;28:2133-44.
13. Miyake K, Karasuyama H. The role of trogocytosis in the modulation of immune cell functions. Cells 2021;10:1255.
14. Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 2019;568:112-6.
15. Olson ML, Mause ERV, Radhakrishnan SV, et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia 2022;36:1943-6.
16. Gang M, Marin ND, Wong P, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood 2020;136:2308-18.
17. Ewen EM, Pahl JHW, Miller M, Watzl C, Cerwenka A. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells. Eur J Immunol 2018;48:355-65.
18. He B, Mai Q, Pang Y, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol 2023;14:1130442.
19. Fontela MG, Snedal S, Planes EM, Abate-daga D. Abstract 887: killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint modulates CAR-T cell effector function. Cancer Res 2023;83:887.
20. Lorenzini T, Cadilha BL, Obeck H et al. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer 2023;129:696-705.
21. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998;391:703-7.
22. Blunt MD, Khakoo SI. Activating killer cell immunoglobulin-like receptors: detection, function and therapeutic use. Int J Immunogenet 2020;47:1-12.
23. Sekine T, Marin D, Cao K, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 2016;128:297-312.
24. Weisdorf D, Cooley S, Wang T, et al. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv 2020;4:740-54.
25. Bachanova V, Weisdorf DJ, Wang T, et al. Donor KIR B genotype improves progression-free survival of non-hodgkin lymphoma patients receiving unrelated donor transplantation. Biol Blood Marrow Transplant 2016;22:1602-7.
26. Blunt MD, Vallejo Pulido A, Fisher JG, et al. KIR2DS2 expression identifies NK cells with enhanced anticancer activity. J Immunol 2022;209:379-90.
27. Gras Navarro A, Kmiecik J, Leiss L, et al. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. J Immunol 2014;193:6192-206.
28. NK cell therapies - artiva. Available from: https://www.artivabio.com/nk-cell-technology/ [Last accessed on 5 Dec 2023].
29. Lemar H, Vohra A, Xie M, Chan I, Lazetic S, Trager J. 128 KIR haplotype can inform donor selection production of allogeneic memory-like CAR NK cells for clinical application. J Immunother Cancer 2021;9:A137.
30. Zhang M, Lam KP, Xu S. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol 2023;14:1207276.
31. Naiyer MM, Cassidy SA, Magri A, et al. KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C. Sci Immunol 2017;2:eaal5296.
32. Rettman P, Blunt MD, Fulton RJ, et al. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors. J Immunother Cancer 2021;9:e001912.
33. Jan CI, Huang SW, Canoll P, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer 2021;9:e003050.
34. Töpfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol 2015;194:3201-12.
35. Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 2021;14:73.
